Skye Bioscience, Inc. (SKYE)
Oxford Ledge is still expanding full research coverage of SKYE. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Skye Bioscience develops CB1-targeting antibody therapies to address obesity and metabolic disorders, focusing on peripheral mechanisms to complement or provide alternatives to existing treatments.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Other material event 2026-06-23
- 8-K Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-05-29
- 8-K Delisting / transfer of listing 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-05-11
- DEF 14A Proxy statement for shareholder vote 2026-04-16
Source: SEC EDGAR.
Annual results
5 years of annual figures for SKYE, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$55.9M | -$1.41 |
| 2024 | — | -$26.6M | -$0.73 |
| 2023 | — | -$37.6M | -$5.37 |
| 2022 | — | -$19.5M | -$8.77 |
| 2021 | — | -$8.5M | -$0.02 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for SKYE. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SKYE in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.